CellPryme Is a Novel Agent That Improves Cell Phenotype, Improves Tumor Control & Overcomes Immunosuppressive TME
Time: 3:00 pm
day: Post-Conference Day - Tackling Solid Tumors
Details:
- CellPryme is a small molecule with up to Phase II clinical experience
- A single exposure of CellPryme during CAR-T expansion significantly increases memory phenotype resulting in exhaustion resistant cells with improved persistence, tumor trafficking/penetrance, and tumor/cell killing
- Combining CellPryme with conventional CAR-T therapy increases CAR-T cell proliferation and overcomes the immunosuppressive tumor microenvironment to improve CAR-T performance
